logo

For the Inventor, By the Inventor

Schlieren, Switzerland

Molecular Partners Ag


USPTO Granted Patents = 22



Trademarks = 2

Forward Citations = 92

Loading Chart...
Loading Chart...

32 inventors (with patents filed for the assignee):

goldMedal Hans Kaspar Binz (14 out of 17 patents)

silverMedal Patrik Forrer (9 out of 15 patents)

bronzeMedal Michael Tobias Stumpp (7 out of 15 patents)

4.  Douglas Phillips (6 out of 6 patents)

5.  Frieder W Merz (6 out of 6 patents)

6.  Ignacio Dolado (5 out of 5 patents)

7.  Ivo Sonderegger (5 out of 5 patents)

8.  Daniel Steiner (5 out of 7 patents)

9.  Maya Gulotti-Georgieva (5 out of 5 patents)

10.  Talitha Bakker (4 out of 4 patents)

11.  Marcel Walser (4 out of 5 patents)

12.  Victor Levitsky (4 out of 4 patents)

13.  Johan Abram Saliba (3 out of 3 patents)

14.  Johannes Schilling (3 out of 3 patents)

15.  Heike Maria Strobel (2 out of 2 patents)


22 patents:

1. 12441772 - Designed ankyrin repeat domain with improved stability (2025-10-14),
2. 12435445 - Designed ankyrin repeat domains with altered surface residues (2025-10-07),
3. 12331090 - Multispecific proteins (2025-06-17),
4. 11834504 - DARPin based multi-specific t-cell engagers (2023-12-05),
5. 11578427 - Designed ankyrin repeat domains with altered surface residues (2023-02-14),
6. 11466062 - Ankyrin repeat binding proteins and their uses (2022-10-11),
7. 11453708 - Designed ankyrin repeat proteins binding to hepatocyte growth factor (2022-09-27),
8. 11332501 - Recombinant binding proteins and their use (2022-05-17),
9. 10717772 - Recombinant binding proteins targeting HER2 and serum albumin, and their uses (2020-07-21),
10. 10646542 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2020-05-12),
11. 10370414 - Binding proteins comprising at least two repeat domains against HER2 (2019-08-06),
12. 10322190 - Capping modules for designed ankyrin repeat proteins (2019-06-18),
13. 10155791 - Recombinant binding proteins and their use (2018-12-18),
14. 9849158 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2017-12-26),
15. 9775912 - Designed repeat proteins binding to serum albumin (2017-10-03),
Company Overview
Molecular Partners AG is a biotechnology company based in Schlieren, Switzerland, specializing in the development of innovative therapeutics using its proprietary DARPins technology platform. This platform enables the creation of targeted protein therapeutics designed to address various diseases, particularly in the fields of oncology and immunology. The company focuses on advancing its pipeline of drug candidates through rigorous research and development, aiming to provide effective treatment options for patients with unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

22 Patents

#5 in Schlieren

#574 in Switzerland

#28,782 in the World

Schlieren, CH
Schlieren, Switzerland

Molecular Partners Ag

Forward Citations = 92

32 inventors:

goldMedal Hans Kaspar Binz (14 out of 17 patents)

silverMedal Patrik Forrer (9 out of 15 patents)

bronzeMedal Michael Tobias Stumpp (7 out of 15 patents)

4.  Douglas Phillips (6 out of 6 patents)

5.  Frieder W Merz (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Molecular Partners Ag. Retrieved from https://idiyas.com/company/molecular-partners-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…